Becton Dickinson & Co (BDX)
258.90
+1.14
(+0.44%)
USD |
NYSE |
Oct 03, 16:00
258.83
-0.07
(-0.03%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 75.11B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 13.84% |
| Valuation | |
| PE Ratio | 46.99 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.895 |
| Price to Book Value | 2.896 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.91 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.647 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 29.62% |
Profile
| Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures pre-filled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of estimated 2023 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business. |
| URL | https://www.bd.com |
| Investor Relations URL | https://investors.bd.com/ |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Nov. 10, 2023 (est.) |
| Last Earnings Release | Aug. 03, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 07, 2023 |
Ratings
Profile
| Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures pre-filled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of estimated 2023 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business. |
| URL | https://www.bd.com |
| Investor Relations URL | https://investors.bd.com/ |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Nov. 10, 2023 (est.) |
| Last Earnings Release | Aug. 03, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 07, 2023 |